The global ankylosing spondylitis treatment market is on a trajectory of substantial growth, with projections indicating a market value of US$ 8.06 billion in 2022, and an estimated crossing of US$ 5.1409 billion by 2032, accompanied by a compound annual growth rate (CAGR) of 4.6% through 2032. These insights come amidst a landscape of evolving treatment modalities and a growing understanding of this chronic inflammatory condition.
Ankylosing spondylitis, a form of arthritis primarily affecting the spine, has seen advancements in treatment options over the years. TNF inhibitor treatments and NSAIDs (Non-steroidal anti-inflammatory drugs) have emerged as cornerstone therapies in managing not only ankylosing spondylitis but also other types of inflammatory arthritis conditions. However, despite the efficacy of these treatments, challenges remain, as highlighted by recent studies and findings.
Get a PDF Sample with Latest Market Insights: https://www.futuremarketinsights.com/reports/sample/rep-gb-12345
At the European Congress of Rheumatology (EULAR) annual meeting, a French study raised concerns regarding the adoption of biosimilars by rheumatologists, citing a lack of confidence in this treatment option. Meanwhile, research published in the European Journal of Integrative Medicine suggested that Moxibustion, a traditional heat therapy, could provide short-term benefits when combined with conventional treatments, offering a glimpse into complementary approaches to managing the condition.
Furthermore, studies conducted at institutions such as the Universita Degli Studi del Molise (Italy) underscored the importance of physiotherapy in improving outcomes for ankylosing spondylitis patients, particularly for those who may not respond adequately to pharmaceutical interventions. This holistic approach to treatment aligns with modern-day trends emphasizing the integration of physical rehabilitation and therapy alongside medical interventions.
Recent research from the University of Medical Sciences (Iran) shed light on the potential of nanocurcumin, derived from turmeric, in modulating immune responses in ankylosing spondylitis patients. The findings suggest promising avenues for exploring novel therapeutic strategies in the management of this condition.
These developments are expected to catalyze increased government investment in research and development, driving innovation and propelling the growth of the ankylosing spondylitis treatment market. As stakeholders collaborate to address the unmet needs of patients and enhance treatment outcomes, the future holds promise for improved quality of life for individuals living with ankylosing spondylitis.
Key Takeaways from Ankylosing Spondylitis Treatment Market Study
- Nonsteroidal anti-inflammatory drugs lead the market as they are looked upon as the first line of treatment for ankylosing spondylitis
- Oral route of administration holds the largest market share due to simplicity of consumption.
- By age group, “adults” contribute to majority of revenue generation as ankylosing spondylitis usually gets initiated in adulthood.
- North America, led by the US, holds the highest market share due to well-established healthcare infrastructure, high incidences of ankylosing spondylitis, and innovations in pharmaceutical industry.
For More Report Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-12345
Ankylosing Spondylitis Treatment Market: Regional Breakdown
The ankylosing spondylitis treatment market shows significant variations across different regions:
- North America: Dominates the market due to:
- Favorable reimbursement policies in the US, especially for biologics.
- High number of approvals for biosimilar drugs by the US Food and Drug Administration (FDA).
- Europe: Experiencing steady growth due to:
- Government investment in research for effective ankylosing spondylitis treatments.
- Likely adoption of biosimilars as patents on biologics expire.
- Asia Pacific: Expected to see the fastest growth due to:
- Increasing awareness of ankylosing spondylitis in countries like India and China.
- Growing disposable income leading to more patients seeking treatment.
This suggests a dynamic market with established dominance in North America, potential for expansion in Europe, and a rapidly emerging market in the Asia Pacific region.
Major Players in the Ankylosing Spondylitis Treatment Market:
- Wyeth
- Mitsubishi Tanabe
- Schering-Plough
- Takeda
- Amgen
- Centocor
- Abbott
- Eisai
- Pfizer
Key Segment:
Drug Class
- Nonsteroidal Anti-inflammatory Drugs
- Anti-Inflammatory Drugs
- Immunosuppressive Drugs
- TNF Blockers
- JAK Inhibitors
- Steroids
- Biologics
- Others
Route of Administration
- Parenteral
- Oral
Application
- Adults
- Juveniles
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
Direct Purchase this Report now: https://www.futuremarketinsights.com/checkout/12345
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
